Canada Markets open in 2 mins

Addex Therapeutics Ltd (ADXN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.8600+0.2300 (+6.34%)
At close: 03:55PM EDT
3.8600 0.00 (0.00%)
Pre-Market: 05:29AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.6300
Open3.6100
Bid3.5500 x 1400
Ask3.8300 x 1400
Day's Range3.4900 - 3.8600
52 Week Range3.1900 - 11.4800
Volume1,141
Avg. Volume3,509
Market Cap22.054M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-2.6580
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Addex Announces Participation in the H.C. Wainwright Global Investment Conference

    Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 - 26, 2022. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at

  • GlobeNewswire

    Addex Announces Participation in the 22nd Bio€quity Europe Conference

    Geneva, Switzerland, May 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Dr. Robert Lütjens, Head of Discovery – Biology, will be attending 22nd Bio€quity Europe Conference taking place May 16 - 18, 2022, in Milan, Italy. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate

  • GlobeNewswire

    Addex Shareholders Approve All Resolutions at Annual General Meeting

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2022 Annual General Meeting (AGM). In line with the Swiss Federal Council COVID-19 Ordinance 3, the company decided to require its shareholders not atten